Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/gut-microbiome.md — the filesystem corpus, unchanged. Not an edit.
17.0 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["longevity", "foundations"]categories: ["longevity", "foundations"]tags: ["aging", "microbiome", "gut", "inflammation", "fecal transplant", "dysbiosis", "mechanisms"]tags: ["aging", "microbiome", "gut", "inflammation", "fecal transplant", "dysbiosis", "mechanisms"]summary: "The community of bacteria, archaea, fungi and viruses living in the human intestine, and a much-claimed but weakly demonstrated lever on aging."summary: "The community of bacteria, archaea, fungi and viruses living in the human intestine, and a much-claimed but weakly demonstrated lever on aging."updated: "2026-08-23"updated: "2026-10-29"humanEvidence: "Microbiome composition tracks health and survival in large human cohorts, and faecal transplant is approved only for recurrent C. difficile; every report of young microbiota extending life is in killifish or mice."humanEvidence: "Microbiome composition tracks health and survival in large human cohorts, and faecal transplant is approved only for recurrent C. difficile; every report of young microbiota extending life is in killifish or mice."issues: ["The oral, skin and vaginal microbiomes are out of scope and are not signposted.", "Diet as an intervention gets one paragraph and deserves more."]issues: ["The oral, skin and vaginal microbiomes are out of scope and are not signposted.", "Diet as an intervention gets one paragraph and deserves more."]------lines 27–37 → 27–3713 unchanged lines not shown
}}`````` **The gut microbiome** is the community of bacteria, archaea, fungi and viruses that live in the human intestine, together with their genes, and the metabolites they produce from what the host eats. Most of it sits in the colon. It has become one of the most heavily invoked mechanisms in the biology of aging — implicated in [[inflammaging|chronic inflammation]], frailty, drug response and cognition — and it is also the mechanism where the distance between what has been shown in animals and what has been shown in people is widest.**The gut microbiome** is the community of bacteria, archaea, fungi and viruses that live in the human intestine, together with their genes, and the metabolites they produce from what the host eats. Most of it sits in the colon. It has become one of the most heavily invoked mechanisms in the biology of aging, implicated in [[inflammaging|chronic inflammation]], frailty, drug response and cognition. It is also the mechanism with the widest gap between what has been shown in animals and what has been shown in people. ## What the community does## What the community does Gut bacteria ferment dietary fibre that human enzymes cannot digest, releasing short-chain fatty acids that colonocytes use as fuel. They transform bile acids, synthesise vitamins, exclude incoming pathogens by occupying niches those pathogens need, and train the developing immune system. Germ-free animals — raised in isolators and never colonised — grow abnormal gut architecture and underdeveloped lymphoid tissue, which is the cleanest demonstration that the community is not a passenger.Gut bacteria ferment dietary fibre that human enzymes cannot digest, releasing short-chain fatty acids that colonocytes use as fuel. They transform bile acids, synthesise vitamins, exclude incoming pathogens by occupying niches those pathogens need, and train the developing immune system. Germ-free animals, raised in isolators and never colonised, grow abnormal gut architecture and underdeveloped lymphoid tissue. That is the cleanest demonstration that the community shapes its host instead of merely living in it. The composition varies enormously between healthy people. Two adults with no illness can share only a modest fraction of their bacterial species while carrying similar metabolic capacities, which is why the field increasingly reports function rather than taxonomy. That variability is also the practical obstacle to defining what a "healthy" microbiome would be, and therefore to defining dysbiosis.The composition varies enormously between healthy people. Two adults with no illness can share only a modest fraction of their bacterial species while carrying similar metabolic capacities, which is why the field increasingly reports function rather than taxonomy. That variability is also the practical obstacle to defining what a "healthy" microbiome would be, and therefore to defining dysbiosis. lines 40–83 → 40–832 unchanged lines not shown
## How it changes with age## How it changes with age The standard summary is that microbial diversity falls with age and pathobionts expand. The evidence is more complicated than that summary.The standard summary is that microbial diversity falls with age and pathobionts expand. The evidence is more complicated. The ELDERMET study characterised faecal microbiota in 178 older Irish adults and found that composition sorted people by where they lived — in the community, in day-hospital, in rehabilitation, or in long-term residential care — and that the sorting tracked dietary quality, frailty, comorbidity and inflammatory markers.[^claesson2012] The gradient is real. What it isolates is not age as such but the diet, medication and confinement that come with institutional care.The ELDERMET study characterised faecal microbiota in 178 older Irish adults and found that composition sorted people by where they lived (in the community, in day-hospital, in rehabilitation, or in long-term residential care) and that the sorting tracked dietary quality, frailty, comorbidity and inflammatory markers.[^claesson2012] The gradient is real, but what it isolates is the diet, medication and confinement that come with institutional care, not age as such. A second reading emphasises divergence rather than loss. Across three cohorts totalling more than nine thousand people, gut microbiomes became increasingly individual from mid-adulthood onward; among adults past about 80, continued drift toward a unique composition was seen in the healthy and was absent in the unwell, and retaining a Bacteroides-dominated community into later life predicted worse survival over four years of follow-up.[^wilmanski2021]A second reading emphasises divergence rather than loss. Across three cohorts totalling more than nine thousand people, gut microbiomes became increasingly individual from mid-adulthood onward; among adults past about 80, continued drift toward a unique composition was seen in the healthy and was absent in the unwell, and retaining a Bacteroides-dominated community into later life predicted worse survival over four years of follow-up.[^wilmanski2021] That result was then qualified by its own field. A reanalysis of roughly 21,000 faecal microbiomes drawn from seven repositories across five continents, spanning ages 18 to 107, found that diversity and uniqueness correlate with chronological aging but not with healthy aging, and that most summary indices obscure the taxonomic changes that carry the biological signal.[^ghosh2022] The generic feature of aging it identified was an increase in disease-associated taxa alongside depletion of a co-abundant set of health-associated ones — a compositional claim, not a diversity claim.Later work in the same field qualified that result. A reanalysis of roughly 21,000 faecal microbiomes drawn from seven repositories across five continents, spanning ages 18 to 107, found that diversity and uniqueness correlate with chronological aging but not with healthy aging, and that most summary indices obscure the taxonomic changes that carry the biological signal.[^ghosh2022] The generic feature of aging it identified was an increase in disease-associated taxa alongside depletion of a co-abundant set of health-associated ones, which is a claim about composition rather than diversity. ```timeline```timeline[[ { "year": "2007", "title": "Human Microbiome Project launched", "text": "The US National Institutes of Health funds a large-scale effort to characterise the microbial communities of healthy people, which supplies the reference data later cohorts are compared against." }, { "year": "2007", "title": "Human Microbiome Project launched", "text": "The US National Institutes of Health funds a large-scale effort to characterise the microbial communities of healthy people, which supplies the reference data later cohorts are compared against." }, { "year": "2012", "title": "Residence, diet and the aging gut", "text": "The ELDERMET cohort links faecal microbiota composition in older adults to living arrangements, diet quality, frailty and inflammatory markers." }, { "year": "2012", "title": "Residence, diet and the aging gut", "text": "The ELDERMET cohort links faecal microbiota composition in older adults to living arrangements, diet quality, frailty and inflammatory markers." }, { "year": "2013", "title": "FDA allows faecal transplant for C. difficile", "text": "The agency states it will exercise enforcement discretion over investigational-new-drug requirements for transplants used against C. difficile infection unresponsive to standard therapy." }, { "year": "2013", "title": "FDA allows faecal transplant for C. difficile", "text": "The agency states it will exercise enforcement discretion over investigational-new-drug requirements for transplants used against C. difficile infection unresponsive to standard therapy." }, { "year": "2017", "title": "Lifespan extension in a vertebrate", "text": "Recolonising middle-aged turquoise killifish with young donor microbiota extends life and preserves activity — the first such result outside invertebrates." }, { "year": "2017", "title": "Lifespan extension in a vertebrate", "text": "Recolonising middle-aged turquoise killifish with young donor microbiota extends life and preserves activity, the first such result outside invertebrates." }, { "year": "2019", "title": "A transplant transmits a fatal infection", "text": "The FDA warns that two immunocompromised recipients developed invasive drug-resistant E. coli infections traced to one donor, whose stool had not been screened for such organisms. One of the two died." }, { "year": "2019", "title": "A transplant transmits a fatal infection", "text": "The FDA warns that two immunocompromised recipients developed invasive drug-resistant E. coli infections traced to one donor, whose stool had not been screened for such organisms. One of the two died." }, { "year": "2022–2023", "title": "Two products approved", "text": "Rebyota, a donor-derived enema, and Vowst, an oral spore preparation, are approved in the US to prevent recurrence of C. difficile infection." }, { "year": "2022-2023", "title": "Two products approved", "text": "Rebyota, a donor-derived enema, and Vowst, an oral spore preparation, are approved in the US to prevent recurrence of C. difficile infection." }, { "year": "2023", "title": "Dysbiosis becomes a hallmark", "text": "The revised hallmarks of aging add dysbiosis as one of twelve. It is the least settled entry on the list, and the only one whose causal contribution rests almost entirely on germ-free and gnotobiotic mice." } { "year": "2023", "title": "Dysbiosis becomes a hallmark", "text": "The revised hallmarks of aging add dysbiosis as one of twelve. It is the least settled entry on the list, and the only one whose causal contribution rests almost entirely on germ-free and gnotobiotic mice." }]]`````` ## Evidence from animals## Evidence from animals The animal literature is where the strong claims come from, and it is genuinely strong within its species.The strong claims come from the animal literature, and within the species studied that literature is strong. Germ-free mice do not develop the age-related rise in circulating pro-inflammatory cytokines that conventionally raised mice develop; a higher proportion of them reach 600 days; and housing germ-free mice with old conventional mice, but not with young ones, raises those cytokines.[^thevaranjan2017] That is a causal chain running from the community to systemic inflammation in a mammal.Germ-free mice do not develop the age-related rise in circulating pro-inflammatory cytokines that conventionally raised mice develop; a higher proportion of them reach 600 days; and housing germ-free mice with old conventional mice, but not with young ones, raises those cytokines.[^thevaranjan2017] Together these results trace a causal chain from the community to systemic inflammation in a mammal. In the African turquoise killifish, a naturally short-lived vertebrate, transferring gut microbiota from young donors into middle-aged fish extended lifespan, kept the recipients more active in old age, and preserved microbial diversity.[^smith2017] In mice, faecal transplant from wild-type animals into two progeroid strains extended both healthspan and lifespan, and colonisation with a single species, *Akkermansia muciniphila*, reproduced much of the benefit; separately, heterochronic transfers in normally aging mice shifted markers of inflammation in the gut, retina and brain in both directions, aged microbiota into young recipients making them worse and young microbiota into aged recipients making them better.[^barcena2019]In the African turquoise killifish, a naturally short-lived vertebrate, transferring gut microbiota from young donors into middle-aged fish extended lifespan, kept the recipients more active in old age, and preserved microbial diversity.[^smith2017] In mice, faecal transplant from wild-type animals into two progeroid strains extended both healthspan and lifespan, and colonisation with a single species, *Akkermansia muciniphila*, reproduced much of the benefit; separately, heterochronic transfers in normally aging mice shifted markers of inflammation in the gut, retina and brain in both directions, aged microbiota into young recipients making them worse and young microbiota into aged recipients making them better.[^barcena2019] None of these is a human result. The progeroid mice were dying of a defined genetic lesion rather than of aging; the killifish is separated from humans by more than 400 million years of evolution; the heterochronic mouse work measured tissue markers, not survival.None of these is a human result. The progeroid mice were dying of a defined genetic lesion rather than of aging, the killifish is separated from humans by more than 400 million years of evolution, and the heterochronic mouse work measured tissue markers instead of survival. > [!caution] The causality gap> [!caution] The causality gap> The standard method for turning a microbiome association into a causal claim is to transfer a human community into a germ-free rodent and see whether the phenotype travels with it. A review of that literature found that about 95% of published human-microbiota-associated rodent studies reported the phenotype transferring — a rate the authors argue is implausibly high and better explained by publication and design bias than by the microbiome causing that many human diseases.[^walter2020] The instrument on which most causal microbiome claims rest is the instrument least able to return a negative result.> The standard method for turning a microbiome association into a causal claim is to transfer a human community into a germ-free rodent and see whether the phenotype travels with it. A review of that literature found that about 95% of published human-microbiota-associated rodent studies reported the phenotype transferring, a rate the authors argue is implausibly high and better explained by publication and design bias than by the microbiome causing that many human diseases.[^walter2020] The method most causal microbiome claims rest on is the one least able to return a negative result. ## Human evidence## Human evidence One clinical use is established. Faecal microbiota transplantation prevents recurrence of *Clostridioides difficile* infection, an indication where the mechanism — restoring colonisation resistance after antibiotics have removed it — is unusually legible. The US regulator moved from enforcement discretion in 2013 to approving two standardised products: Rebyota, a donor-derived rectal suspension, in November 2022, and Vowst, an oral preparation of purified spores, in April 2023.[^fda2022] Both are licensed to prevent recurrence, not to treat an initial infection, and neither is licensed for anything else.One clinical use is established. Faecal microbiota transplantation prevents recurrence of *Clostridioides difficile* infection, an indication where the mechanism (restoring colonisation resistance after antibiotics have removed it) is unusually easy to follow. The US regulator moved from enforcement discretion in 2013 to approving two standardised products: Rebyota, a donor-derived rectal suspension, in November 2022, and Vowst, an oral preparation of purified spores, in April 2023.[^fda2022] Both are licensed to prevent recurrence, not to treat an initial infection, and neither is licensed for anything else. Beyond that indication the human evidence is associative. Cohort studies relate composition to frailty, mortality and inflammatory markers, and cannot separate the microbiome from the diet, medication burden and illness that shape it. Randomised trials of probiotics in older adults exist in quantity but use a wide range of strains and outcome measures and report conflicting results; the field has not produced a probiotic with a demonstrated effect on survival, frailty or any accepted measure of [[biological-age]].[^hutchinson2021] Commercial [[dietary-supplements|supplements]] sold on microbiome claims are not held to that standard at all, and microbiome testing sits alongside the other services discussed under [[biohacking]] where the measurement outruns anything actionable derived from it.Beyond that indication the human evidence is associative. Cohort studies relate composition to frailty, mortality and inflammatory markers, and cannot separate the microbiome from the diet, medication burden and illness that shape it. Randomised trials of probiotics in older adults exist in quantity but use a wide range of strains and outcome measures and report conflicting results; the field has not produced a probiotic with a demonstrated effect on survival, frailty or any accepted measure of [[biological-age]].[^hutchinson2021] Commercial [[dietary-supplements|supplements]] sold on microbiome claims are not held to that standard at all, and microbiome testing belongs with the other services discussed under [[biohacking]] whose measurements outrun anything actionable that can be derived from them. Diet is the intervention with the clearest effect on the community and the least clear effect on aging. Fibre intake changes composition within days, and the dietary patterns associated with longevity in [[blue-zones|long-lived populations]] are fibre-rich; whether the microbiome mediates any part of that association, or merely registers it, is untested. The same ambiguity applies to [[exercise-and-aging|exercise]] and to [[caloric-restriction]], both of which alter the community in rodents. Spaceflight shifts the community as well, in a setting where diet, activity and medication happen to be logged in unusual detail; those changes are covered under [[space-medicine]].Diet is the intervention with the clearest effect on the community and the least clear effect on aging. Fibre intake changes composition within days, and the dietary patterns associated with longevity in [[blue-zones|long-lived populations]] are fibre-rich; whether the microbiome mediates any part of that association, or merely registers it, is untested. The same ambiguity applies to [[exercise-and-aging|exercise]] and to [[caloric-restriction]], both of which alter the community in rodents. Spaceflight shifts the community as well, in a setting where diet, activity and medication happen to be logged in unusual detail; those changes are covered under [[space-medicine]]. lines 85–97 → 85–991 unchanged line not shown
Three features of the field make overstatement easy. Composition can be measured cheaply and at scale, so associations are abundant. The community is modifiable in principle, which makes every association read as a potential intervention. And the germ-free rodent supplies an apparatus that converts an association into a causal-looking experiment without leaving the animal facility.Three features of the field make overstatement easy. Composition can be measured cheaply and at scale, so associations are abundant. The community is modifiable in principle, which makes every association read as a potential intervention. And the germ-free rodent supplies an apparatus that converts an association into a causal-looking experiment without leaving the animal facility. The result is a pattern this wiki flags elsewhere in geroscience: a mechanism with genuine biology behind it, an intervention approved for one narrow infection, and a public claim structure that reaches from mood to dementia to lifespan. [[metformin]] and [[rapamycin]] occupy the same position from the pharmacological side — a real signal in mice and an unresolved question in people. The [[geroscience-hypothesis]] predicts that intervening on any upstream driver of aging should move many outcomes at once; the microbiome is a candidate driver for which the prediction has not been tested in humans at all.The result is a pattern this wiki flags elsewhere in geroscience: a mechanism with real biology behind it, an intervention approved for one narrow infection, and public claims that reach from mood to dementia to lifespan. [[metformin]] and [[rapamycin]] occupy the same position on the pharmacological side, with a real signal in mice and an unresolved question in people. The [[geroscience-hypothesis]] predicts that intervening on any upstream driver of aging should move many outcomes at once; the microbiome is a candidate driver for which the prediction has not been tested in humans at all. ## Outlook## Outlook The tractable questions are narrower than the popular ones. Whether transplant benefits any condition other than recurrent *C. difficile* is being tested in registered trials; several indications have produced mixed or null results, and the honest position as of 2026 is that no second indication is established. Whether defined bacterial consortia can replace donor stool would narrow the safety problem that donor screening only partly contains: recipients have died after transplants that carried drug-resistant or pathogenic *E. coli* from donors who had passed screening, in incidents the US regulator publicised in 2019 and 2020.[^fda2019]The tractable questions are narrower than the popular ones. Whether transplant benefits any condition other than recurrent *C. difficile* is being tested in registered trials; several indications have produced mixed or null results, and as of 2026 no second indication is established. Defined bacterial consortia, if they can replace donor stool, would narrow the safety problem that donor screening only partly contains: recipients have died after transplants that carried drug-resistant or pathogenic *E. coli* from donors who had passed screening, in incidents the US regulator publicised in 2019 and 2020.[^fda2019] For aging specifically, the obstacle is the same one that constrains [[aging-biomarkers|biomarker]] work generally: no microbiome measure has been accepted as a surrogate endpoint, and none has the standing that even a contested composite such as an [[epigenetic-clock|epigenetic clock]] has acquired, so a trial aimed at [[healthspan]] must be powered on clinical outcomes, which makes it large and slow. Until such a trial reports, the position that fits the evidence is that the aging gut community is a real and measurable phenomenon whose causal contribution to human aging is unquantified, and that its treatment as an established lever — in the way [[cellular-senescence]] or [[immunosenescence]] are treated — runs ahead of what anyone has shown. The strongest objection to the whole programme is that the correlations survive because the microbiome is downstream of everything: of diet, drugs, [[cancer|disease]], activity and confinement. A marker of how a person has lived is not thereby a target.For aging specifically, the obstacle is the same one that constrains [[aging-biomarkers|biomarker]] work generally: no microbiome measure has been accepted as a surrogate endpoint, and none has the standing that even a contested composite such as an [[epigenetic-clock|epigenetic clock]] has acquired, so a trial aimed at [[healthspan]] must be powered on clinical outcomes, which makes it large and slow. Until such a trial reports, the position that fits the evidence is that the aging gut community is a real and measurable phenomenon whose causal contribution to human aging is unquantified. Treating it as an established lever, in the way [[cellular-senescence]] or [[immunosenescence]] are treated, runs ahead of what anyone has shown. The strongest objection to the whole programme is that the correlations survive because the microbiome is downstream of everything: of diet, drugs, [[cancer|disease]], activity and confinement. On that view the microbiome is a marker of how a person has lived, and being a marker does not make it a target. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
102 lines are the same in both revisions, and 44 of them are not shown. Neither revision here is necessarily the current article — read Gut microbiome for the text this wiki stands behind today.